The project aims to set up a new drug discovery platform that integrates several in silico technologies
  (innovative screening, interactive molecular modelling, interaction and behavior prediction, augmented
  3D-visualization and de-novo in silico synthesis) with human cellular disease model experiments.

  The partners believe thata combination of their respective expertises will significantly enhance drug lead
  discovery on new promising drug targets. The drug discovery platform will be set up by working out a case
  that demonstrates the working of this platform and its efficiency in reducing drug discovery time and costs.

  The case will be the discovery of compounds that interfere with a certain protein-protein interaction that is
  crucial in the development of heart failure. The consortium plans to discover both commercially available
  compounds and generate new de-novo synthesized compounds that interfere with this interaction. The working   of these compounds will be predicted in silico and tested onhuman heart cells and human cellular disease   models, derived from heart restricted progenitor cells.